The earnings call discussed new investments in AI Company II and Neurona Therapeutics, along with the buyback program's impact on NAV discount. The fund sources cash for buybacks by selling liquid holdings, managing positions like Oxford Nanopore to balance buybacks, operating costs, and new investments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing